Technology area: Chemistry & Materials
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Epibone Inc. currently manages a concentrated company patent portfolio within the Chemistry & Materials technology area. The prosecution activity is presently limited to 1 pending office action. This matter is being handled by 1 distinct examiner, indicating a narrow front for current USPTO engagement. Because the portfolio's active footprint is restricted to 1 distinct art unit, the company's immediate legal strategy is focused on a specific regulatory niche. This concentration allows for a focus on the specific examination standards of that unit.
The busiest examiner for this portfolio is MUTREJA, JYOTI NAGPAUL, who is responsible for the 1 pending office action currently on file. This examiner represents the entirety of the company's active examination pipeline. For a practitioner, this means that the outcome of this interaction with MUTREJA, JYOTI NAGPAUL will define the success of the portfolio's expansion. The concentration of 1 busiest examiner pending case suggests that the firm's current prosecution resources are not divided across multiple challenges. This point of contact simplifies the administrative burden of tracking deadlines and examiner preferences.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MUTREJA, JYOTI NAGPAUL | 1 | 81.1% | +4.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17963304 | ALTERNATING PRESSURE AND VACUUM SYSTEM FOR DECELLULARIZING A BONE MATRIX | MUTREJA, JYOTI NAGPAUL | 2d overdue |
| Art Unit | Apps |
|---|---|
| 1798 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17963304 | ALTERNATING PRESSURE AND VACUUM SYSTEM FOR DECELLULARIZING A BONE MATRIX | MUTREJA, JYOTI NAGPAUL | 1798 | §102 | Non-Final OA | 2d overdue | Pending | Oct 11, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEpibone Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jyoti Nagpaul Mutreja has the most, with 1 of Epibone Inc.'s pending office actions.
Mostly Chemistry & Materials (USPTO Tech Center 1700), based on where its pending office actions are examined.
